Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01728103 · ClinicalTrials.gov registry record

Prospective Collection of Female Specimens for Testing With Gen-Probe APTIMA (Registered Trademark) Assays

A clinical trial, sponsored by Gen-Probe, Incorporated.

Terminated
Registry status
1,336
Enrollment target

NCT01728103 is a clinical trial that was terminated before completion, run by Gen-Probe, Incorporated. The registered enrollment target is 1,336 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01728103 was terminated before completion, sponsored by Gen-Probe, Incorporated.

TERMINATED
Registry status
1,336 participants
Enrollment target

Study Summary

The objective of this study is to obtain female first-catch urine, vaginal, cervical and endocervical swabs for testing with multiple APTIMA Assays on the Gen-Probe PANTHER® and TIGRIS® Systems.

Interventions

  • DEVICE APTIMA® Trichomonas vaginalis & APTIMA® COMBO 2® Assays

Trial Details

FieldValue
Enrollment Target 1,336 participants
Start Date 2013-01

Sponsor

Gen-Probe, Incorporated

12 total trials

What the Registry Record Tells You About NCT01728103

The ClinicalTrials.gov registry entry for NCT01728103 describes a study currently listed as terminated, categorized as an unspecified phase. The registered enrollment target is 1,336 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Gen-Probe, Incorporated, which has 12 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 1 intervention - of which APTIMA® Trichomonas vaginalis & APTIMA® COMBO 2® Assays is the first listed.

NCT01728103 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT01728103 about?

NCT01728103 is a clinical study titled "Prospective Collection of Female Specimens for Testing With Gen-Probe APTIMA (Registered Trademark) Assays". The objective of this study is to obtain female first-catch urine, vaginal, cervical and endocervical swabs for testing with multiple APTIMA Assays on the Gen-Probe PANTHER® and TIGRIS® Systems.

What is the current status of trial NCT01728103?

This trial is currently terminated. The enrollment target is 1,336 participants. The study started on 2013-01.

What interventions are being tested in trial NCT01728103?

The interventions under investigation include: APTIMA® Trichomonas vaginalis & APTIMA® COMBO 2® Assays (DEVICE).

Who is sponsoring clinical trial NCT01728103?

This trial is sponsored by Gen-Probe, Incorporated, which has 12 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.